TIMELESS Promotes Tumor Progression by Enhancing Macrophages Recruitment in Ovarian Cancer

Xin Xing, Fei Gu, Lanyu Hua, Xiaoxiao Cui, Dongxue Li, Zhi‐Yong Wu, Rong ZhangFrontiers in Oncology 2021 · DOI

Abstract

Ovarian cancer (OV) remains a leading cause of gynecological cancer-related mortality due to late-stage diagnosis and limited therapeutic options. This study identifies TIMELESS (TIM), a core circadian clock gene, as a critical driver of OV progression. Our findings demonstrate that TIM is significantly overexpressed in OV tissues and correlates with advanced clinical stages. Beyond promoting tumor cell proliferation and migration, TIM actively reshapes the tumor microenvironment by recruiting pro-tumor macrophages via chemokine signaling. These results suggest that TIM serves as a promising prognostic biomarker and a potential target for immunotherapy in ovarian cancer.

Introduction

Ovarian cancer is characterized by high lethality, with a five-year survival rate often falling below 45%. A growing body of evidence suggests that disruptions in circadian rhythms—the internal biological processes that follow a 24-hour cycle—are linked to increased cancer risk and progression. However, the specific molecular mechanisms by which circadian genes influence the ovarian tumor microenvironment have remained largely unexplored. This research focuses on TIMELESS (TIM), investigating its role as a potential oncogene and its impact on immune cell infiltration.

Methods

The study employed a comprehensive "bench-to-bedside" methodology combining bioinformatics with laboratory validation:

  • Bioinformatics Analysis: mRNA and protein expression levels were analyzed using TCGA, GTEx, and CPTAC databases. The TIMER tool was utilized to correlate gene expression with immune cell infiltration.
  • Validation in Independent Cohorts: Four GEO datasets (GDS3592, GSE18520, GSE12470, GSE26712) were used to confirm TIM expression patterns across diverse patient groups.
  • Functional Assays: In vitro experiments using SKOV3 and OVCAR3 cell lines involved siRNA-mediated knockdown of TIM to assess its effect on cell growth, migration, and invasion.
  • In Vivo Modeling: Mouse xenograft models were used to evaluate the impact of TIM silencing on tumor growth in a living system.
  • Clinical Histology: Immunohistochemistry (IHC) was performed on 176 human OV samples to validate the clinical relevance of TIM protein levels.

Results

TIM is Overexpressed Across Multiple Ovarian Cancer Cohorts

Analysis of large-scale genomic and proteomic data revealed a consistent and significant upregulation of TIM in ovarian cancer compared to normal tissues. mRNA levels were elevated in TCGA-GTEx and four independent GEO datasets. Protein analysis via CPTAC further confirmed this trend at the translational level.

TIM expression is significantly upregulated in ovarian cancer across mRNA (A, C), protein (B), and clinical IHC (D) datasets.

Clinical Validation and Prognostic Impact

Immunohistochemical staining of 176 clinical samples demonstrated that 75.6% of patients exhibited high TIM protein expression. This overexpression was not uniform across all stages; rather, high TIM levels were significantly associated with more advanced disease stages and higher tumor grades, suggesting its utility as a prognostic marker.

TIM Drives Tumor Growth and Metastatic Potential

Functional studies revealed that silencing TIM dramatically inhibited the proliferation, migration, and invasive capabilities of ovarian cancer cells. In animal models, mice injected with TIM-knockdown cells developed significantly smaller and lighter tumors compared to controls, confirming TIM's role in promoting tumor growth in vivo.

Modulation of the Tumor Microenvironment

A key discovery of this study is the link between TIM and the recruitment of macrophages. Bioinformatics and IHC staining showed a strong positive correlation between TIM levels and CD68+ macrophage infiltration. Mechanistically, high TIM expression appears to trigger the release of chemokines such as CCL2 and CCL5, which act as signals to draw macrophages into the tumor site, potentially facilitating an immunosuppressive environment.

Discussion

This study establishes TIMELESS as a major player in ovarian cancer pathogenesis. Unlike many oncogenes driven by frequent mutations, TIM's impact stems primarily from its massive overexpression—the gene is "cranked up" too high rather than broken. By acting as a bridge between the circadian clock and the immune microenvironment, TIM promotes a "pro-tumor" niche through macrophage recruitment.

While these findings highlight TIM as a viable target for immunotherapy, challenges remain. Future work must identify the precise signaling pathways connecting TIM to chemokine production and develop strategies to target TIM within tumors without disrupting systemic circadian rhythms. Nonetheless, TIM stands out as a robust biomarker for identifying high-risk patients and a novel therapeutic vulnerability in ovarian cancer.

Summary updated

Abstract

Our study unveiled a novel function of highly expressed TIM associated with immune cell especially macrophages infiltration in OV. TIM may serve as a potential prognostic biomarker and immunotherapy target for OV patients.
BibTeX
@inproceedings{xing2021timeless,
  author = {Xin Xing and Fei Gu and Lanyu Hua and Xiaoxiao Cui and Dongxue Li and Zhi‐Yong Wu and Rong Zhang},
  title = {{TIMELESS Promotes Tumor Progression by Enhancing Macrophages Recruitment in Ovarian Cancer}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.732058},
}
Figure